|
1
|
Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mizokami M, Yokosuka O, Takehara T,
Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F,
Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination
with and without ribavirin for 12 weeks in treatment-naive and
previously treated Japanese patients with genotype1 hepatitis C: An
open-label, randomised, phase 3 trial. Lancet Infect Dis.
15:645–653. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumada H, Suzuki Y, Ikeda K, Toyota J,
Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et
al: Daclatasvir plus Asunaprevir for chronic HCV Genotype1b
infection. Hepatology. 59:2083–2091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morgan RL, Baack B, Smith BD, Yartel A,
Pitasi M and Falck-Ytter Y: Eradication of hepatitis C virus
infection and the development of hepatocellular carcinoma: A
meta-analysis of observational studies. Ann Intern Med.
158:329–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arase Y, Kobayashi M, Suzuki F, Suzuki Y,
Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, et
al: Effect of type 2 diabetes on risk for malignancies includes
hepatocellular carcinoma in chronic hepatitis C. Hepatology.
57:964–973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oze T, Hiramatsu N, Yakushijin T, Miyazaki
M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, et al:
Post-treatment levels of α-fetoprotein predict incidence of
hepatocellular carcinoma after interferon therapy. Clin
Gastroenterol Hepatol. 12:1186–1195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Asahina Y, Tsuchiya K, Nishimura T,
Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K,
Nakanishi H, et al: α-fetoprotein levels after interferon therapy
and risk of hepatocarcinogenesis in chronic hepatitis C.
Hepatology. 58:1253–1262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Makiyama A, Itoh Y, Kasahara A, Imai Y,
Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K,
et al: Characteristics of patients with chronic hepatitis C who
develop hepatocellular carcinoma after a sustained response to
interferon therapy. Cancer. 101:1616–1622. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirakawa M, Ikeda K, Arase Y, Kawamura Y,
Yatsuji H, Hosaka T, Sezaki H, Akuta N, Kobayashi M, Saitoh S, et
al: Hepatocarcinogenesis following HCV RNA eradication by
interferon in chronic hepatitis patients. Intern Med. 47:1637–1643.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hayashi T, Tamori A, Nishikawa M, Morikawa
H, Enomoto M, Sakaguchi H, Habu D, Kawada N, Kubo S, Nishiguchi S
and Shiomi S: Differences in molecular alterations of
hepatocellular carcinoma between patients with a sustained
virological response and those with hepatitis C virus infection.
Liver Int. 29:126–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio
E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, et al:
Genome-wide association study identifies TLL1 variant associated
with development of hepatocellular carcinoma after eradication of
hepatitis C virus infection. Gastroenterol. 152:1383–1394. 2017.
View Article : Google Scholar
|
|
12
|
Theise ND, Park YN, Curado MP, Sakamoto M,
Franceschi S, Torbenson M, Hytiroglou P, Wee A and Kudo M: WHO
classification of tumours of the digestive system. Lyon: IARC
Press; pp. 205–216. 2010
|
|
13
|
Ichida F, Tsuji T, Omata M, Inoue K,
Kamimura T, Yamada G, Hino K, Yokosuka O and Suzuki H: New Inuyama
classification; new criteria for histological assessment of chronic
hepatitis. Int Hepatol Commun. 6:112–119. 1996. View Article : Google Scholar
|
|
14
|
Umeno Y, Ogasawara S, Akiba J, Hattori S,
Kusano H, Nakashima O, Koga H, Torimura T, Yamakawa R and Yano H:
Regulator of G-protein signaling 5 enhances portal vein invasion in
hepatocellular carcinoma. Oncol Lett. 15:1763–1770. 2018.PubMed/NCBI
|
|
15
|
Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao
H, Lu L, Jiang W, Xu Y, Feng B, et al: New classification of liver
biopsy assessment for fibrosis in chronic hepatitis B patients
before and after treatment. Hepatology. 65:1438–1450. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Calderaro J, Rousseau B, Amaddeo G, Mercey
M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay
D, et al: Programmed death ligand 1 expression in hepatocellular
carcinoma: Relationship with clinical and pathological features.
Hepatology. 64:2038–2046. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu M, Chen X, Zhang J, Wang D, Fang X,
Wang X, Wang G, Chen G, Jiang X, Xia H and Wang Y: Over-expression
of regulator of G protein signaling 5 promotes tumor metastasis by
including ephithelial-mesenchymal transition in hepatocellular
carcinoma cells. J Surg Oncol. 108:192–196. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsujikawa H, Masugi Y, Yamazaki K, Itano
O, Kitagawa Y and Sakamoto M: Immunohistochemical molecular
analysis indicates hepatocellular carcinoma subgroups that reflect
tumor aggressiveness. Hum Pathol. 50:24–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calderaro J, Couchy G, Imbeaud S, Amaddeo
G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage
P, et al: Histological subtypes of hepatocellular carcinoma are
related to gene mutations and molecular tumour classification. J
Hepatol. 67:727–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goossens N, Sun X and Hoshida Y: Molecular
classification of hepatocellular carcinoma: Potential therapeutic
implications. Hepatol Oncol. 2:371–379. 2015. View Article : Google Scholar
|
|
22
|
George SL, Bacon BR, Brunt EM,
Mihindukulasuriya KL, Hoffmann J and Di Bisceglie AM: Clinical,
virologic histologic, and biochemical outcomes after successful HCV
therapy: A 5-year follow-up of 150 patients. Hepatology.
49:729–738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sasaki R, Yamasaki K, Abiru S, Komori A,
Nagaoka S, Saeki A, Hashimoto S, Bekki S, Kugiyama Y, Kuno A, et
al: Serum wisteria floribunda agglutinin-positive Mac-2 binding
protein values predict the development of hepatocellular carcinoma
among patients with chronic hepatitis C after sustained virological
response. PLoS One. 10:e1290532015. View Article : Google Scholar
|
|
24
|
Bekki Y, Yoshizumi T, Shimoda S, Itoh S,
Harimoto N, Ikegami T, Kuno A, Narimatsu H, Shirabe K and Maehara
Y: Hepatic stelleate cells secreting WFA+-M2BP: Its role
in biological interactions with Kupffer cells. J Gastroenterol
Hepatol. 32:1387–1393. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Friedman SL: Hepatic stellate cells:
Protean, multifunctional, and enigmatic cells of the liver. Physiol
Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Motoyama H, Komiya T, Thuy le TT, Tamori
A, Enomoto M, Morikawa H, Iwai S, Uchida-Kobayashi S, Fujii H,
Hagihara A, et al: Cytoglobin is expressed in hepatic stellate
cells, but not in myofibroblasts, in normal and fibrotic human
liver. Lab Invest. 94:192–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Couvelard A, Scoazec JY and Feldmann G:
Expression of cell-cell and cell-matrix adhesion proteins by
sinusoidal endothelial cells in the normal and cirrhotic human
liver. Am J Pathol. 143:738–752. 1993.PubMed/NCBI
|
|
28
|
Nonaka H, Tanaka M, Suzuki K and Miyajima
A: Development of murine hepatic sinusoidal endothelial cells
characterized by the expression of hyaluronan receptors. Dev Dyn.
236:2258–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martinez-Hernandez A and Martinez J: The
role of capillarization in hepatic failure: Studies in carbon
tetrachloride-induced cirrhosis. Hepatology. 14:864–874. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Blanc JF, Bioulac-Sage P and Rosenbaum J:
Hepatic stellate cells and liver fibrogenesis. Gastroenterol Clin
Biol. 21:869–879. 1997.(In French). PubMed/NCBI
|
